Jessica Ley

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff et al. · Clinical Cancer Research · 2020 · 365 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

Douglas R. Adkins, Jessica Ley, Prakash Neupane et al. · The Lancet Oncology · 2019 · 124 citations

Medicine, Oncology, Pharmacology +8

Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

Giacomo Oliveira, Ann Marie Egloff, Alexander B. Afeyan et al. · Science Immunology · 2023 · 116 citations · Full text

Medicine, Immunology, Oncology +17

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Loren Michel, Jessica Ley, Tanya M. Wildes et al. · Oral Oncology · 2016 · 88 citations · Full text

Medicine, Oncology, Pharmacology +15

Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Jessica Ley, Paul Mehan, Tanya M. Wildes et al. · Oncology · 2013 · 46 citations · Full text

Medicine, Oncology, Radiation Oncology +12